Previous studies have correlated initial CEA and CA19-9 levels with important clinicopathological characteristics, such as lymph node metastasis [31], recurrences [35], peritoneal metastasis [36] and survival [37], in GC patients. This evidence concerns the gene CEACAM5 and gastric cancer.